Connect with us

Best Undervalued Stocks To Buy Now? 5 Blue-Chip Stocks To Watch

Should investors consider these blue-chip stocks now that they are trading at more attractive valuations?
The post Best Undervalued Stocks To Buy Now? 5 Blue-Chip Stocks To Watch appeared first on Stock Market News, Quotes, Charts and Financial Informatio

Published

on

Check Out These Blue-Chip Stocks In The Stock Market Today

The tech sell-off, especially among smaller cap growth stocks, is rippling through the stock market. And if you’re looking for bargains to carry into the new year with you, there are certainly some attractive options to consider now. If you’re wondering where to invest your money today, why not take a look at these blue-chip stocks. 

What are some of the traits that blue-chip stocks typically possess? The best ones consistently grow their revenue and earnings per share, and have strong balance sheets. Put simply, you want to be investing in companies that are consistently growing, no matter what’s going on with the broader market. But that doesn’t mean these companies are foolproof. They too, will be subject to market forces and will rise and fall along the broader market movements. Considering many of them have been under pressure in recent months, would you consider putting up a list of top blue-chip stocks to buy in the stock market today?

Top Blue-Chip Stocks To Watch Right Now

FedEx

Package delivery kingpin FedEx surprised investors with its stronger-than-expected earnings on Thursday. For its second fiscal quarter, the company reported an earnings per share of $4.83 on revenue of $23.5 billion for the quarter. Despite the impressive quarter, labor inflation is still an issue, but the company appears to be handling it well. Recall in September, the higher labor inflation and supply chain disruptions led the company to cut full fiscal year 2022 guidance. Thankfully, higher revenue per shipment helped to offset these costs.

Notably, a key highlight of the company’s earnings call would be the update to its fiscal 2022 profit outlook. Thanks to the current momentum in its business, FedEx is reinstating its initial estimates after lowering them in September. For the fiscal year, the company is now expecting an annual earnings per share between $20.50 to $21.50. At the same time, FedEx also announced a $5 billion share repurchase program as well. It could suggest that management believes the stock is undervalued. With FedEx seemingly kicking into high gear across the board, would FDX stock make your list of blue-chip stocks to buy now?

FDX stock chart
Source: TD Ameritrade TOS

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

AT&T

Many investors have long left AT&T for good. It has been a painful year for AT&T stock investors, to say the least. But that could soon change. Yesterday, Simon Flannery, an analyst at Morgan Stanley, placed an ‘Overweight’ rating on T stock. Flannery believes that the company will become a more streamlined company focused on its core communications operations after its WarnerMedia entertainment division completes the merger with Discovery (NASDAQ: DISCA). In addition to that, the analyst also argued that the company is poised to benefit greatly from the rising demand of 5G network services.

What’s more, AT&T CEO John Stankey provided an update to shareholders last week. He characterized current wireless industry demand trends as healthy, saying that any seasonal uptick in competition remains broadly in line with historical trends. Stankey is also confident in the sustainability of AT&T’s wireless momentum. Furthermore, the company’s deployment plans are on track. In fact, in the coming years, investors can expect multiple opportunities from the country’s largest fiber network, including improved consumer and business penetration. Given this exciting piece of news, is T stock worth investing in right now?

T stock chart
Source: TD Ameritrade TOS

[Read More] Best Copper Mining Stocks To Buy In 2021? 4 To Watch This Week

ExxonMobil

Another blue chip stock to consider is oil and natural gas giant ExxonMobil. By and large, ExxonMobil is an industry juggernaut thanks to its massive refinery operations. The likes of which cater to the increasing energy needs of the world today. With ExxonMobil’s current presence in the market, Exxon should keep pumping profits from its oil wells for decades. Not to mention it also has a large natural gas business, which allows it to diversify from its oil demand.

No doubt, the biggest driver of profitability for major oil companies is the oil price itself. As with many commodities, oil prices tend to move up and down over the course of the year due to seasonality. With the potential for a colder winter, it sets the stage for higher oil prices in the year to come. To top it all off, the company’s current dividend yield of 5.7% could be another reason why investors love this stock so much. Considering all this, would you include XOM stock on your watchlist going into 2022?

XOM Stock chart
Source: TD Ameritrade TOS

MercadoLibre

MercadoLibre operates one of the largest ecommerce platforms in Latin America. The company’s platform is accessible to consumers across 18 Latin American countries. And it is actively taking measures to grow in these markets. For instance, it announced the acquisition of Redelcom earlier this week. Redelcom is a Chilean payment services provider of high-tech point-of-sale (POS) terminals. This acquisition would synergize well with MercadoLibre’s POS division, MercadoPago. With Redelcom, MercadoLibre seems to be taking aim at smaller upcoming names in the Latin American retail scene.

Moreover, the company also saw green across the board in its latest quarterly earnings report posted last month. In it, MercadoLibre posted a total revenue of $1.86 billion, marking a solid year-over-year increase of 66%. Over the same period, it also reported gains of over 530% in both its net income and earnings per share. Additionally, its unique active users grew to 78.7 million in the latest quarter. After sliding around 40% from its all-time high, would MELI stock be one of the top undervalued stocks to buy?

MELI stock chart
Source: TD Ameritrade TOS

[Read More] 4 Artificial Intelligence Stocks To Watch Right Now

Clorox

Arguably one one of the most contrarian picks here is Clorox. For the uninitiated, it is a global manufacturer and marketer of consumer and professional products. In brief, the company’s flagship offerings include its bleach and cleaning products. If you’re worried about inflation, it’s comforting to know that Clorox has the pricing power to mitigate those effects. Should Omicron pose a bigger threat, demand for cleaning products could jump again. 

After an unprecedented growth in 2020, it is looking at extremely difficult year-over-year comparisons. But if we look at it on a 2-year basis, the growth rate remains respectable. With much of the downside appearing to be baked in, investors may be in a position to make a decent return. In addition, the company has a history of delivering consistent double-digit returns on capital and profit margins. Safe to say, consumers have and continue to turn to Clorox amid the current pandemic. Should investors be doing the same with CLX stock?

CLX stock chart
Source: TD Ameritrade TOS

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post Best Undervalued Stocks To Buy Now? 5 Blue-Chip Stocks To Watch appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Uncategorized

Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45%…

Published

on

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45% of US respondents in 2023, according to the latest Harris Poll data. That’s exactly the same as the previous year.

Pharma’s highest point was in February 2021 — as Covid vaccines began to roll out — with a 62% positive US perception, and helping the industry land at an average 55% positive sentiment at the end of the year in Harris’ 2021 annual assessment of industries. The pharma industry’s reputation hit its most recent low at 32% in 2019, but it had hovered around 30% for more than a decade prior.

Rob Jekielek

“Pharma has sustained a lot of the gains, now basically one and half times higher than pre-Covid,” said Harris Poll managing director Rob Jekielek. “There is a question mark around how sustained it will be, but right now it feels like a new normal.”

The Harris survey spans 11 global markets and covers 13 industries. Pharma perception is even better abroad, with an average 58% of respondents notching favorable sentiments in 2023, just a slight slip from 60% in each of the two previous years.

Pharma’s solid global reputation puts it in the middle of the pack among international industries, ranking higher than government at 37% positive, insurance at 48%, financial services at 51% and health insurance at 52%. Pharma ranks just behind automotive (62%), manufacturing (63%) and consumer products (63%), although it lags behind leading industries like tech at 75% positive in the first spot, followed by grocery at 67%.

The bright spotlight on the pharma industry during Covid vaccine and drug development boosted its reputation, but Jekielek said there’s maybe an argument to be made that pharma is continuing to develop innovative drugs outside that spotlight.

“When you look at pharma reputation during Covid, you have clear sense of a very dynamic industry working very quickly and getting therapies and products to market. If you’re looking at things happening now, you could argue that pharma still probably doesn’t get enough credit for its advances, for example, in oncology treatments,” he said.

Read More

Continue Reading

Spread & Containment

I created a ‘cosy game’ – and learned how they can change players’ lives

Cosy, personal games, as I discovered, can change the lives of the people who make them and those who play them.

Published

on

By

Cosy games exploded in popularity during the pandemic. Takoyaki Tech/Shutterstock

The COVID pandemic transformed our lives in ways many of us are still experiencing, four years later. One of these changes was the significant uptake in gaming as a hobby, chief among them being “cosy games” like Animal Crossing: New Horizons (2020).

Players sought comfort in these wholesome virtual worlds, many of which allowed them to socialise from the safety of their homes. Cosy games, with their comforting atmospheres, absence of winning or losing, simple gameplay, and often heartwarming storylines provided a perfect entry point for a new hobby. They also offered predictability and certainty at a time when there wasn’t much to go around.

Cosy games are often made by small, independent developers. “Indie games” have long been evangelised as the purest form of game development – something anyone can do, given enough perseverance. This means they can provide an entry point for creators who hadn’t made games before, but were nevertheless interested in it, enabling a new array of diverse voices and stories to be heard.

In May 2020, near the start of the pandemic, the small poetry game A Solitary Spacecraft, which was about its developer’s experience of their first few months in lockdown, was lauded as particularly poignant. Such games showcase a potential angle for effective cosy game development: a personal one.

Personal themes are often explored through cosy games. For instance, Chicory and Venba (both released in 2023) tackle difficult topics like depression and immigration, despite their gorgeous aesthetics. This showcases the diversity of experiences on display within the medium.

However, as the world emerges from the pandemic’s shadow, the games industry is facing significant challenges. Economic downturns and acquisitions have caused large layoffs across the sector.

Historically, restructurings like these, or discontent with working conditions, have led talented laid-off developers to create their own companies and explore indie development. In the wake of the pandemic and the cosy game boom, these developers may have more personal stories to tell.

Making my own cosy game

I developed my own cosy and personal game during the pandemic and quickly discovered that creating these games in a post-lockdown landscape is no mean feat.

What We Take With Us (2023) merges reality and gameplay across various digital formats: a website, a Discord server that housed an online alternate reality game and a physical escape room. I created the game during the pandemic as a way to reflect on my journey through it, told through the videos of game character Ana Kirlitz.

The trailer for my game, What We Take With Us.

Players would follow in Ana’s footsteps by completing a series of ten tasks in their real-world space, all centred on improving wellbeing – something I and many others desperately needed during the pandemic.

But creating What We Take With Us was far from straightforward. There were pandemic hurdles like creating a physical space for an escape room amid social distancing guidelines. And, of course, the emotional difficulties of wrestling with my pandemic journey through the game’s narrative.

The release fared poorly, and the game only garnered a small player base – a problem emblematic of the modern games industry.

These struggles were starkly contrasted by the feedback I received from players who played the game, however.

This is a crucial lesson for indie developers: the creator’s journey and the player’s experience are often worlds apart. Cosy, personal games, as I discovered, can change the lives of those who play them, no matter how few they reach. They can fundamentally change the way we think about games, allow us to reconnect with old friends, or even inspire us to change careers – all real player stories.

Lessons in cosy game development

I learned so much about how cosy game development can be made more sustainable for creators navigating the precarious post-lockdown landscape. This is my advice for other creators.

First, collaboration is key. Even though many cosy or personal games (like Stardew Valley) are made by solo creators, having a team can help share the often emotional load. Making games can be taxing, so practising self-care and establishing team-wide support protocols is crucial. Share your successes and failures with other developers and players. Fostering a supportive community is key to success in the indie game landscape.

Second, remember that your game, however personal, is a product – not a reflection of you or your team. Making this distinction will help you manage expectations and cope with feedback.

Third, while deeply considering your audience may seem antithetical to personal projects, your game will ultimately be played by others. Understanding them will help you make better games.

The pandemic reignited the interest in cosy games, but subsequent industry-wide troubles may change games, and the way we make them, forever. Understanding how we make game creation more sustainable in a post-lockdown, post-layoff world is critical for developers and players alike.

For developers, it’s a reminder that their stories, no matter how harrowing, can still meaningfully connect with people. For players, it’s an invitation to embrace the potential for games to tell such stories, fostering empathy and understanding in a world that greatly needs it.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.


Adam Jerrett does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Government

The SNF Institute for Global Infectious Disease Research announces new advisory board

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in…

Published

on

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.

Credit: Lori Chertoff/The Rockefeller University

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.

This international advisory board was created in part to give guidance on how to best use SNFiRU’s resources, as well as bring forward innovative ideas concerning new avenues of research, public education, community engagement, and partnership projects.

SNFiRU was established to strengthen readiness for and response to future health crises, building on the scientific advances and international collaborations forged in the context of the COVID-19 pandemic. Launched with a $75 million grant from the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI), the institute provides a framework for international scientific collaboration to foster research innovations and turn them into practical health benefits.

SNFiRU’s mission is to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally. To speed this work, the institute launched numerous initiatives in its inaugural year. For instance, SNFiRU awarded 31 research projects in 29 different Rockefeller laboratories for over $5 million to help get collaborative new research efforts off the ground. SNFiRU also supports the Rockefeller University Hospital, where clinical studies are conducted, and brought on board its first physician-scientist through Rockefeller’s Clinical Scholars program. “One of the surprises was the scope of interest from Rockefeller scientists in using their talents to tackle important infectious disease problems,” says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor in Virology at Rockefeller and director of SNFiRU. “The research topics range from the biology of infectious agents to the dynamics of the immune response to pathogens, and also include a number of infectious disease-adjacent studies.”

In the past 12 months, SNFiRU often brought together scientists studying different aspects of infectious disease as a way to spur new collaborations. In addition to hosting its first annual day-long symposium, SNFiRU initiated a Young Scientist Forum for students and post-doctoral fellows to meet regularly, facilitating cross-laboratory thinking. A bimonthly seminar series has also been established on campus.

Another aim of SNFiRU is to develop relationships with community-based organizations, as well as design and participate in community-engaged research, with a focus on low-income and minority communities. To that end, SNFiRU is helping develop a research project on Chagas disease, a tropical parasitic infection prevalent in Latin America that can cause congestive heart failure and gastrointestinal complications if left untreated. The project will bring together clinicians practicing at health centers in New York, Florida, Texas, and California and basic scientists from multiple institutions to help the communities that are most impacted.

“The SNFiRU international advisory board convenes globally recognized leaders with distinguished biomedical expertise, unrivalled experience in pandemic preparedness and response, and a shared commitment to translating scientific advancements into equitably distributed benefits in real-world settings,” says SNF Co-President Andreas Dracopoulos. “The advisory board will advance the institute’s indispensable mission, which SNF is proud to support as a key part of our Global Health Initiative, and we look forward to seeing breakthroughs in the lab drive better outcomes in lives around the globe.”

The new advisory board will hold its first meeting on April 11th, 2024, following the second annual SNF Institute for Global Infectious Disease Research Symposium at Rockefeller.

Its members are: Rafi Ahmed of Emory University School of Medicine, Cori Bargmann of The Rockefeller University, Yasmin Belkaid of the Pasteur Institute, Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development, Esper Kallas of of the Butantan Institute, Sharon Lewin of the University of Melbourne Doherty Institue, Carl Nathan of Weill Cornell Medicine, Rino Rappuoli of Fondazione Biotecnopolo di Siena and University of Siena, and Herbert “Skip” Virgin of Washington University School of Medicine and UT Southwestern Medical Center.


Read More

Continue Reading

Trending